Breakthrough Designation & Medicine Adaptive Pathways to Patients – What Does It All mean?

Featuring:

Richard Barker,
Director,
CASMI

James Anderson,
Director of EU Industry & External Partnerships,
GSK

Nathalie Seigneuret,
Senior Scientific Project Manager,
Innovative Medicines Initiative (IMI)

John Parkinson,
Director of the Clinical Practice Research Database,
MHRA

Samantha Roberts,
Head of Science Policy,
Friends of Cancer Research

The webinar is supported by:

imi casmi efpia VitalTransformation

How To Use Your Meeting Tools:

Raise your hand

Dial in or headphones

Ask a question



Breakthrough Designation & Medicine Adaptive Pathways to Patients – What Does It All mean?

Featuring:

Richard Barker,
Director,
CASMI

James Anderson,
Director of EU Industry & External Partnerships,
GSK

Nathalie Seigneuret,
Senior Scientific Project Manager,
Innovative Medicines Initiative (IMI)

John Parkinson,
Director of the Clinical Practice Research Database,
MHRA

Samantha Roberts,
Head of Science Policy,
Friends of Cancer Research

The webinar is supported by:

imi casmi efpia VitalTransformation

EAMS – UK Early Access to Medicines Scheme:

- Knit regulatory oversight, health technology assessment and commissioning, seamlessly together.
- Focus is on providing data for health technology assessments

Process/Criteria:

1. Product categorised as a Promising Innovative Medicine (PIM) - similar to the FDA's Breakthrough designation.
2. MHRA to speed up health technology assessment providing confidence to use and pay for unlicensed products
3. Reduction in development timelines from phase III data could be a 9 – 12 months.

Breakthrough Designation & Medicine Adaptive Pathways to Patients – What Does It All mean?

Featuring:

Richard Barker,
Director,
CASMI

James Anderson,
Director of EU Industry & External Partnerships,
GSK

Nathalie Seigneuret,
Senior Scientific Project Manager,
Innovative Medicines Initiative (IMI)

John Parkinson,
Director of the Clinical Practice Research Database,
MHRA

Samantha Roberts,
Head of Science Policy,
Friends of Cancer Research

The webinar is supported by:

imi casmi efpia VitalTransformation